Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 243

The DOI matches its Crossref record.

Which threshold for ER positivity? a retrospective study based on 9639 patients

Open access
Yi, M., Huo, L., Koenig, K.B., Mittendorf, E.A., Meric-Bernstam, F., Kuerer, H.M., Bedrosian, I., Buzdar, A.U., Symmans, W.F., Crow, J.R., Bender, M., Shah, R.R., Hortobagyi, G.N., Hunt, K.K.·2014·Annals of Oncology
DOI 10.1093/annonc/mdu053
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/annonc/mdu053

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

No references could be resolved yet.

Research works printed but not linked: 25

  1. Bardou, 2003, Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases, J Clin Oncol, 21, 1973, 10.1200/JCO.2003.09.099 · DOI · Paper page
  2. Hammond, 2010, American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer, J Clin Oncol, 28, 2784, 10.1200/JCO.2009.25.6529 · DOI · Paper page
  3. Layfield, 2000, Assessment of tissue estrogen and progesterone receptor levels: a survey of current practice, techniques, and quantitation methods, Breast J, 6, 189, 10.1046/j.1524-4741.2000.99097.x · doi:10.1046/j.1524-4741.2000.99097.x
  4. Putti, 2005, Breast pathology practice: most common problems in a consultation service, Histopathology, 47, 445, 10.1111/j.1365-2559.2005.02246.x · doi:10.1111/j.1365-2559.2005.02246.x
  5. Dowsett, 2005, Retrospective analysis of time to recurrence in the ATAC trial according to hormone receptor status: an hypothesis-generating study, J Clin Oncol, 23, 7512, 10.1200/JCO.2005.01.4829 · DOI · Paper page
  6. Dowsett, 2008, Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, alone or in combination trial, J Clin Oncol, 26, 1059, 10.1200/JCO.2007.12.9437 · DOI · Paper page
  7. Elledge, 2000, Estrogen receptor (ER) and progesterone receptor (PgR), by ligand-binding assay compared with ER, PgR and pS2, by immuno-histochemistry in predicting response to tamoxifen in metastatic breast cancer: a Southwest Oncology Group Study, Int J Cancer, 89, 111, 10.1002/(SICI)1097-0215(20000320)89:2<111::AID-IJC2>3.0.CO;2-W · DOI · Paper page
  8. Regan, 2006, Re-evaluating adjuvant breast cancer trials: assessing hormone receptor status by immunohistochemical versus extraction assays, J Natl Cancer Inst, 98, 1571, 10.1093/jnci/djj415 · DOI · Paper page
  9. Viale, 2007, Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1–98, J Clin Oncol, 25, 3846, 10.1200/JCO.2007.11.9453 · DOI · Paper page
  10. Viale, 2008, Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors—International Breast Cancer Study Group, J Clin Oncol, 26, 1404, 10.1200/JCO.2007.10.6393 · DOI
  11. Davies, 2011, Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials, Lancet, 378, 771, 10.1016/S0140-6736(11)60993-8 · DOI · Paper page
  12. Iwamoto, 2012, Estrogen receptor (ER) mRNA and ER-related gene expression in breast cancers that are 1% to 10% ER-positive by immunohistochemistry, J Clin Oncol, 30, 729, 10.1200/JCO.2011.36.2574 · DOI · Paper page
  13. Allred, 2009, NCCN Task Force Report: estrogen receptor and progesterone receptor testing in breast cancer by immunohistochemistry, J Natl Compr Canc Netw, 7, S1, 10.6004/jnccn.2009.0079 · DOI
  14. Harvey, 1999, Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer, J Clin Oncol, 17, 1474, 10.1200/JCO.1999.17.5.1474 · DOI · Paper page
  15. Di Cosimo, 2010, Management of breast cancer with targeted agents: importance of heterogeneity. [corrected], Nat Rev Clin Oncol, 7, 139, 10.1038/nrclinonc.2009.234 · DOI · Paper page
  16. Jensen, 2003, The estrogen receptor: a model for molecular medicine, Clin Cancer Res, 9, 1980
  17. Goldhirsch, 2005, Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005, Ann Oncol, 16, 1569, 10.1093/annonc/mdi326 · DOI · Paper page
  18. Day, 1999, Health-related quality of life and tamoxifen in breast cancer prevention: a report from the National Surgical Adjuvant Breast and Bowel Project P-1 Study, J Clin Oncol, 17, 2659, 10.1200/JCO.1999.17.9.2659 · DOI · Paper page
  19. Fisher, 1998, Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study, J Natl Cancer Inst, 90, 1371, 10.1093/jnci/90.18.1371 · DOI · Paper page
  20. Buzdar, 2006, Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial, Lancet Oncol, 7, 633, 10.1016/S1470-2045(06)70767-7 · DOI · Paper page
  21. Paik, 2004, A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer, N Engl J Med, 351, 2817, 10.1056/NEJMoa041588 · DOI · Paper page
  22. Fan, 2006, Concordance among gene-expression-based predictors for breast cancer, N Engl J Med, 355, 560, 10.1056/NEJMoa052933 · DOI · Paper page
  23. Loi, 2007, Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade, J Clin Oncol, 25, 1239, 10.1200/JCO.2006.07.1522 · DOI · Paper page
  24. Paik, 2006, Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer, J Clin Oncol, 24, 3726, 10.1200/JCO.2005.04.7985 · DOI · Paper page
  25. Kraus, 2012, Semi-quantitative immunohistochemical assay versus oncotype DX® qRT-PCR assay for estrogen and progesterone receptors: an independent quality assurance study, Mod Pathol, 25, 869, 10.1038/modpathol.2011.219 · DOI

Cited by

See all 243

Metadata

Authors
Yi, M., Huo, L., Koenig, K. B., Mittendorf, E. A., Meric-Bernstam, F., Kuerer, H. M., Bedrosian, I., Buzdar, A. U., Symmans, W. F., Crow, J. R., Bender, M., Shah, R. R., Hortobagyi, G. N., & Hunt, K. K.
Venue
Annals of Oncology
Publisher
Elsevier BV
Published
2014-05
Volume
25
Issue
5
Pages
1004-1011
ISSN
0923-7534 (ISSN-L)
DOI
10.1093/annonc/mdu053
OpenAlex
W2149495821
Cited by
243
References
0
FWCI
3.50
Type
journal article
Language
en
Open access
bronze
Licence
Funders
National Institutes of Health (CA016672)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Which threshold for ER positivity? a retrospective study based on 9639 patients. https://app.cochat.ai/papers/10.1093/annonc/mdu053
The paper
Yi, M., Huo, L., Koenig, K. B., Mittendorf, E. A., Meric-Bernstam, F., Kuerer, H. M., Bedrosian, I., Buzdar, A. U., Symmans, W. F., Crow, J. R., Bender, M., Shah, R. R., Hortobagyi, G. N., & Hunt, K. K. (2014). Which threshold for ER positivity? a retrospective study based on 9639 patients. Annals of Oncology. https://doi.org/10.1093/annonc/mdu053

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.